What are the key teaching points for lazertinib (generic name) in adults with advanced EGFR‑mutated non‑small cell lung cancer?

Lazertinib Teaching Points for Advanced EGFR-Mutated NSCLC

Lazertinib (240 mg orally once daily) is FDA-approved exclusively in combination with amivantamab as first-line treatment for adults with locally advanced or metastatic NSCLC harboring EGFR exon 19 deletions or exon 21 L858R substitution mutations 1.

Indication and Patient Selection

Confirm EGFR mutation status before initiating therapy using an FDA-approved test on tumor tissue or plasma specimens. If plasma testing is negative, tissue testing is mandatory 1. Lazertinib is indicated only for:

• EGFR exon 19 deletions
• EGFR exon 21 L858R substitution mutations

The drug is not approved as monotherapy despite showing activity in clinical trials 2, 3. Current FDA approval requires combination with amivantamab 4, 1.

Dosing and Administration

Standard dose: 240 mg orally once daily with or without food, in combination with amivantamab 1.

Key Administration Points:

• Swallow tablets whole—do not crush, split, or chew 1
• Administer lazertinib before amivantamab when given on the same day 1
• Continue until disease progression or unacceptable toxicity 1

Missed Dose Protocol:

• If ≤12 hours late: Take the missed dose immediately
• If >12 hours late: Skip and resume at next scheduled time 1

If Vomiting Occurs:

• Do not retake the dose
• Resume at next scheduled time 1

Required Concomitant Medications

Mandatory VTE Prophylaxis:

Administer anticoagulant prophylaxis for the first 4 months of treatment to prevent venous thromboembolic events 1. After 4 months without VTE signs/symptoms, consider discontinuation at provider discretion 1.

Dermatologic Prophylaxis:

Initiate at treatment start 1:

• Alcohol-free emollient cream (isopropanol-free, ethanol-free)
• Limit sun exposure during treatment and for 2 months after
• Protective clothing and broad-spectrum UVA/UVB sunscreen
• Consider prophylactic oral antibiotics to reduce dermatologic reactions 1

Adverse Event Profile

Most Common Adverse Events (from clinical trials):

Dermatologic toxicities predominate 2, 3, 5:

• Rash (37-54%)
• Pruritus (34-35%)
• Paronychia (strong signal in post-market surveillance) 5
• Dermatitis acneiform 5

Neurologic toxicities 2, 3, 5:

• Paresthesia (33-35%)
• Peripheral neuropathy (strong signal) 5
• Peripheral sensory neuropathy 5

Gastrointestinal 2, 3:

• Diarrhea (47%)

Critical Safety Distinction:

Lazertinib demonstrates superior cardiac safety compared to osimertinib 6, 7:

• No clinically relevant QTcF prolongation at any dose 7
• No clinically significant LVEF decreases 7
• Only 1 patient (grade 2 decreased LVEF) experienced cardiac failure-associated AE, which resolved without dose modification 7
• Predicted QTcF increase at 240 mg: 2.2 msec (upper 90% CI: 3.6 msec) 7

Most adverse events are mild to moderate in severity 2, 3. No drug-related rash or pruritus of grade ≥3 reported in the LASER201 study 2.

Clinical Efficacy Context

While lazertinib monotherapy showed promising activity in clinical trials (ORR 55-70%, median PFS 11-25 months) 2, 3, the FDA approval is based on combination therapy with amivantamab 4, 1. The MARIPOSA trial demonstrated that amivantamab plus lazertinib is a preferred first-line option 4.

CNS Activity:

Lazertinib demonstrates excellent brain penetration 8, 6, 9:

• Intracranial ORR: 50-86% 3, 9
• Median intracranial PFS: 15.2 months 9
• Activity maintained even in patients with leptomeningeal metastases 9

Important Contraindications and Precautions

Do not use immune checkpoint inhibitors (ICIs) before exhausting standard EGFR-targeted therapies in EGFR-mutated NSCLC 10. ICIs show limited efficacy and increase risk of toxicity with subsequent TKI treatment, including potential for severe pneumonitis (38% with durvalumab plus osimertinib) 10.

Patient Counseling Points

1. Take exactly as prescribed with amivantamab—this is not optional
2. Start VTE prophylaxis immediately and continue for 4 months minimum
3. Begin skin care regimen before first dose: alcohol-free moisturizers, sun protection
4. Report immediately: chest pain, shortness of breath, leg swelling (VTE), severe rash, numbness/tingling
5. Expect dermatologic and neurologic side effects—most are manageable and mild-moderate
6. Cardiac safety profile is favorable compared to other third-generation EGFR TKIs
7. Continue treatment until disease progression—do not stop without consulting oncology team

Clinical Pearls

• Lazertinib is mutant-selective and wild-type-sparing, creating a wide therapeutic index 8, 7
• Superior CNS penetration makes it particularly valuable for patients with brain metastases 8, 6, 9
• Lower cardiotoxicity risk compared to osimertinib may make it preferable in patients with cardiac comorbidities 6, 7
• T790M resistance mutation activity: While lazertinib showed efficacy against T790M in phase 1/2 trials 3, the FDA approval is for first-line treatment in combination, not for T790M-positive disease after prior EGFR TKI failure